ShopSpell

Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence [Hardcover]

$196.99       (Free Shipping)
56 available
  • Category: Books (Technology & Engineering)
  • ISBN-10:  113863199X
  • ISBN-10:  113863199X
  • ISBN-13:  9781138631991
  • ISBN-13:  9781138631991
  • Publisher:  CRC Press
  • Publisher:  CRC Press
  • Pages:  306
  • Pages:  306
  • Binding:  Hardcover
  • Binding:  Hardcover
  • SKU:  113863199X-11-MPOD
  • SKU:  113863199X-11-MPOD
  • Item ID: 107136126
  • Seller: ShopSpell
  • Ships in: 2 business days
  • Transit time: Up to 5 business days
  • Delivery by: Sep 30 to Oct 02
  • Notes: Brand new books. Buy now.

This groundbreaking volume explores a Global Health Care Equivalency system powered by AI and quantum computing on secure blockchains. It provides insights into transforming healthcare through quantum encryption, AI diagnostics, offering a roadmap for achieving worldwide healthcare equity for policy makers and technology specialists.

Frank J. Boehm has worked as a nanotechnology consultant, technology scout, product designer, research associate, and academic writer/editor for international corporations and university laboratories. Self-taught in nanotechnology and nanomedicine, Frank has developed numerous concepts for advanced nanomedical diagnostic and therapeutic systems. In 2009, he founded NanoApps Medical, Inc. to develop innovative and cost-effective nanomedical solutions for global benefit, and later co-founded NanoApps Athletics, Inc. in 2019. His published works include his first book on nanomedical device design (2013), multiple book chapters, journal articles, and an in-depth paper on Human Brain/Cloud Interface. Currently, Frank is focused on a three-book series exploring the convergence of nanotechnology, nanomedicine, AI, and quantum computing to achieve global healthcare equivalency.

Raj Bawa is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm founded in 2002. Trained as a microbiologist and biochemist, he serves as a registered patent agent, scientific advisor to Teva Pharmaceutical Industries (since 2010), professor at Northern Virginia Community College (since 2004), and vice president/chief IP officer at Guanine, Inc. (since 2016). Dr. Bawa previously worked at the US Patent & Trademark Office (1990s-2002) as a primary examiner. He has led various research initiatives, including a CDC grant to develop an assay for carbapenemase-resistant bacteria. His education includes degrees in microbiology (BSc), cancer biology (MS), biolCģ

Add Review